Skip to content

Clinical trials

Phase 4 Renal Insufficiency, Chronic trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Renal Insufficiency, Chronic Phase: Phase 4 Clear all

312 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20013
20025
20037
20047
20056
200610
20074
200822
200923
201012
201115
201216
201317
20147
201520
201611
201711
201817
201910
20207
20219
202211
202314
202417
202514
202611

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed153
Unknown status67
Recruiting29
Terminated23
Withdrawn16
Not yet recruiting11
Active, not recruiting9
Enrolling by invitation3
Suspended1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Amgen11
VA Office of Research and Development5
Abbott4
Chinese University of Hong Kong4
Indiana University4
Seoul National University Hospital4
University Medical Center Groningen4
AstraZeneca3
Chinese PLA General Hospital3
Dong-A University3

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Renal Insufficiency, Chronic312
Anemia28
Kidney Failure, Chronic28
Hypertension24
Diabetes Mellitus, Type 222
Proteinuria22
Renal Insufficiency20
Hyperparathyroidism, Secondary15
Kidney Diseases15
Cardiovascular Diseases14

Trials

Showing 1 to 25 of 312. Each trial links to its page on Pharma Observatory.

212 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.